Methods for variant detection

US2021285033A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2021285033-A1
Application numberUS-202017084797-A
CountryUS
Kind codeA1
Filing dateOct 30, 2020
Priority dateNov 25, 2015
Publication dateSep 16, 2021
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention can be used to provide a more efficient and less error-prone method of detecting variants in DNA, such as SNPs and indels. The invention also provides a method for performing inexpensive multiplex assays.

First claim

Opening claim text (preview).

1 . A method of detecting one or more variations in a target DNA sequence, the method comprising: (a) providing a first reaction mixture comprising: (i) a first allele specific oligonucleotide primer and a second allele specific oligonucleotide primer, both having a cleavage domain positioned 5′ of a blocking group and 3′ of a position of variation, the blocking group linked at or near the end of the 3′-end of the oligonucleotide primer, wherein the blocking group prevents primer extension and/or inhibits the first and second allele specific oligonucleotide primers from serving as a template for DNA synthesis, (ii) a nucleic acid sample that may or may not have the target DNA sequence, wherein the target DNA sequence may or may not have the variation, (iii) a cleaving enzyme, and (iv) a polymerase, wherein the polymerase is a high-discrimination mutant H784Q Taq polymerase; (b) hybridizing the first and second allele specific oligonucleotide primers to the target DNA sequence, if present in the sample, to form a double-stranded substrate; (c) cleaving the first and second allele specific oligonucleotide primers hybridized to the target DNA sequence, if the first and second allele specific oligonucleotide primers are complementary at the variation, with the cleaving enzyme at a point within or adjacent to the cleavage domain to remove the blocking group from the first and second allele specific oligonucleotide primers; and (d) extending the first and second allele specific oligonucleotide primers with the high-discrimination mutant H784Q Taq polymerase; and (e) providing a second reaction mixture comprising: (i) the first allele specific oligonucleotide primer and a third allele specific oligonucleotide primer, both having a cleavage domain positioned 5′ of a blocking group and 3′ of a position of variation, the blocking group linked at or near the end of the 3′-end of the first and second allele specific oligonucleotide primers, wherein the blocking group prevents primer extension and/or inhibits the first and third allele specific oligonucleotide primers from serving as a template for DNA synthesis, (ii) a nucleic acid sample that may or may not have the target DNA sequence, wherein the target DNA sequence may or may not have the variation, (iii) a cleaving enzyme, and (iv) a polymerase, wherein the polymerase is a high-discrimination mutant H784Q Taq polymerase; (f) hybridizing the first and third allele specific oligonucleotide primers to the target DNA sequence, if present in the sample, to form a double-stranded substrate; (g) cleaving the first and third oligonucleotide primers hybridized to the target DNA sequence, if the first and third allele specific oligonucleotide primers are complementary at the variation, with the cleaving enzyme at a point within or adjacent to the cleavage domain to remove the blocking group from the first and third allele specific oligonucleotide primers; and (h) extending the first and third allele specific oligonucleotide primers with the high-discrimination mutant H784Q Taq polymerase. 2 . The method of claim 1 , wherein the first, second, and third allele specific oligonucleotide primers contain: (a) a 5′ tail sequence that comprises a universal primer sequence and a reporter probe sequence that corresponds to an allele specific oligonucleotide primer, wherein the 5′ tail sequence is non-complementary to the target DNA sequence; (b) a region complementary to the target DNA sequence; and (c) an allele specific domain. 3 . The method of claim 2 , wherein the allele specific domain is capable of being cleaved by an RNase H enzyme when hybridized to the target DNA sequence. 4 . The method of claim 1 , wherein the cleavage domain is comprised of at least one RNA base, and the cleaving enzyme cleaves between the position complementary to the variation and the RNA base. 5 . The method of claim 1 , wherein the cleavage domain is comprised of one or more 2′-modified nucleosides, and the cleaving enzyme cleaves between the position complementary to the variation and the one or more 2′-modified nucleosides. 6 . The method of claim 5 , wherein the one or more 2′-modified nucleosides are 2′-fluoronucleosides. 7 . The method of claim 1 , wherein the cleaving enzyme is a hot start cleaving enzyme that is reversibly inactivated through interaction with an antibody at lower temperatures. 8 . The method of claim 1 , wherein the cleaving enzyme is a hot start cleaving enzyme that is thermostable and has reduced activity at lower temperatures. 9 . The method of claim 1 , wherein the cleaving enzyme is a chemically modified hot start cleaving enzyme that is thermostable and has reduced activity at lower temperatures. 10 . The method of claim 9 , wherein the chemically modified hot start cleaving enzyme is a chemically modified Pyrococcus abyssi RNase H2. 11 . The method of claim 1 , wherein the high-discrimination mutant H784Q Taq polymerase is reversibly inactivated via chemical, aptamer, or antibody modification. 12 . A method of visualization of multiple different fluorescent signals from allelic amplification plots, the method comprising: (a) using three fluorescent signals from multiple fluorescent dye signals in a single reaction well, subtracting a lowest fluorescence Dye 3 from fluorescence signals from Dye 1 and Dye 2 ; (b) calculating the distance of data from an origin and an angle from one of the axis with an equation Distance ⁢ ⁢ from ⁢ ⁢ origin = ( Δ ⁢ R ⁢ n D ⁢ y ⁢ e ⁢ 1 ) 2 + ( Δ ⁢ R ⁢ n D ⁢ y ⁢ e ⁢ 2 ) 2 Angle = tan - 1 ⁡ (

Assignees

Inventors

Classifications

  • Allele specific primer extension · CPC title

  • incorporating a non-extendable or blocking moiety · CPC title

  • incorporating bases where the precise position of the bases in the nucleic acid string is important · CPC title

  • incorporating target specific and non-target specific sites · CPC title

  • incorporating/generating a new priming site · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2021285033A1 cover?
The invention can be used to provide a more efficient and less error-prone method of detecting variants in DNA, such as SNPs and indels. The invention also provides a method for performing inexpensive multiplex assays.
Who is the assignee on this patent?
Integrated Dna Tech Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6827. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Sep 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).